CEP70, centrosomal protein 70, 80321

N. diseases: 20; N. variants: 1
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0024117
Disease: Chronic Obstructive Airway Disease
Chronic Obstructive Airway Disease 		0.100 GeneticVariation disease GWASCAT The genetics of smoking in individuals with chronic obstructive pulmonary disease. 29631575 2018
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.040 Biomarker phenotype BEFREE Our previous worked show that centrosomal protein 70 (Cep70) regulates breast cancer growth and metastasis. 28632150 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.040 Biomarker phenotype BEFREE Is Centrosomal Protein 70, a Centrosomal Protein with New Roles in Breast Cancer Dissemination and Metastasis, a Facilitator of Epithelial-Mesenchymal Transition? 28109768 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.040 Biomarker phenotype BEFREE Herein, we identify centrosomal protein 70 (Cep70) as an important factor that mediates breast cancer growth and metastasis. 28063737 2017
CUI: C0027627
Disease: Neoplasm Metastasis
Neoplasm Metastasis 		0.040 AlteredExpression phenotype BEFREE Cep70 expression correlates with clinicopathological parameters of pancreatic cancer, including histological grade, pathological tumor node metastasis stage, lymph node metastasis, and carbohydrate antigen 19-9 level. 26893288 2016
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.030 Biomarker group BEFREE Our technology may therefore provide a practical and low-cost strategy to potentiate many cancer immunotherapies used to treat solid tumors, including T-cell therapy, vaccines, and BITE platforms.<b>Significance:</b> A new nanotechnology approach can promote T-cell therapy for solid tumors.<i>Cancer Res; 78(13); 3718-30.©2018 AACR</i>. 29760047 2018
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.030 Biomarker group BEFREE Together, these results demonstrate a critical role for Cep70 in the development and progression of breast cancer and have important implications in the diagnosis and therapy of this malignancy. 28063737 2017
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms 		0.030 Biomarker group BEFREE We have developed a humanized bi-specific T-cell engager (BiTE) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell surface antigen present on a range of malignancies and cancer-initiating cells. 28811962 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.020 Biomarker group BEFREE Our technology may therefore provide a practical and low-cost strategy to potentiate many cancer immunotherapies used to treat solid tumors, including T-cell therapy, vaccines, and BITE platforms.<b>Significance:</b> A new nanotechnology approach can promote T-cell therapy for solid tumors.<i>Cancer Res; 78(13); 3718-30.©2018 AACR</i>. 29760047 2018
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.020 Biomarker disease BEFREE Together, these results demonstrate a critical role for Cep70 in the development and progression of breast cancer and have important implications in the diagnosis and therapy of this malignancy. 28063737 2017
CUI: C0006142
Disease: Malignant neoplasm of breast
Malignant neoplasm of breast 		0.020 Biomarker disease BEFREE These data demonstrate that Cep70 mediates paclitaxel sensitivity in breast cancer. 28632150 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.020 Biomarker group BEFREE Cep70 promotes breast cancer cell proliferation and colony formation in vitro and increases tumor growth in mice. 28063737 2017
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 Biomarker disease BEFREE Together, these results demonstrate a critical role for Cep70 in the development and progression of breast cancer and have important implications in the diagnosis and therapy of this malignancy. 28063737 2017
CUI: C0678222
Disease: Breast Carcinoma
Breast Carcinoma 		0.020 Biomarker disease BEFREE These data demonstrate that Cep70 mediates paclitaxel sensitivity in breast cancer. 28632150 2017
CUI: C1306459
Disease: Primary malignant neoplasm
Primary malignant neoplasm 		0.020 Biomarker group BEFREE Together, these results demonstrate a critical role for Cep70 in the development and progression of breast cancer and have important implications in the diagnosis and therapy of this malignancy. 28063737 2017
CUI: C0027651
Disease: Neoplasms
Neoplasms 		0.020 Biomarker group BEFREE Cep70 also stimulates colony formation in soft agar and enhances tumor growth in mice. 26893288 2016
CUI: C0003125
Disease: Anorexia Nervosa
Anorexia Nervosa 		0.010 Biomarker disease BEFREE Components of the biochemical inflammatory response (COX-2, PGE<sub>2</sub>, TBARS, 15d-PGJ<sub>2</sub>, ERK, p65 NFκB) and glucocorticoid receptor -GR- expression and the scores on the impulsivity measures in the BARRATT, EDI and BITE questionnaires showed a significant correlation within the AN patients group. 31398429 2020
CUI: C0021125
Disease: Impulsive Behavior
Impulsive Behavior 		0.010 Biomarker phenotype BEFREE Components of the biochemical inflammatory response (COX-2, PGE<sub>2</sub>, TBARS, 15d-PGJ<sub>2</sub>, ERK, p65 NFκB) and glucocorticoid receptor -GR- expression and the scores on the impulsivity measures in the BARRATT, EDI and BITE questionnaires showed a significant correlation within the AN patients group. 31398429 2020
CUI: C0007645
Disease: Cellulitis and abscess NOS (disorder)
Cellulitis and abscess NOS (disorder) 		0.010 Biomarker disease BEFREE HAND CELLULITIS AND ABSCESS FROM A KINKAJOU BITE: A Case Report and Review of Kinkajou Bites in Humans. 31725116 2019
CUI: C0003873
Disease: Rheumatoid Arthritis
Rheumatoid Arthritis 		0.010 AlteredExpression disease BEFREE TL1A antibody prevented the DcR3-Fc inhibitory effects on CEP70 expression in RA-FLS. 28696795 2018
CUI: C0029408
Disease: Degenerative polyarthritis
Degenerative polyarthritis 		0.010 AlteredExpression disease BEFREE CEP70 expression was dose-dependently downregulated by DcR3-Fc in RA-FLS but was not downregulated in OA-FLS. 28696795 2018
CUI: C0280100
Disease: Solid Neoplasm
Solid Neoplasm 		0.010 Biomarker phenotype BEFREE Our technology may therefore provide a practical and low-cost strategy to potentiate many cancer immunotherapies used to treat solid tumors, including T-cell therapy, vaccines, and BITE platforms.<b>Significance:</b> A new nanotechnology approach can promote T-cell therapy for solid tumors.<i></i>. 29760047 2018
CUI: C0376358
Disease: Malignant neoplasm of prostate
Malignant neoplasm of prostate 		0.010 Biomarker disease BEFREE Here, an <i>in situ</i> forming depot-injectable polymeric system was used to deliver BiJ591, a bispecific T-cell engager (BiTE) targeting both prostate-specific membrane antigen (PSMA) and the CD3 T-cell receptor in prostate cancer. 29891487 2018
CUI: C0600139
Disease: Prostate carcinoma
Prostate carcinoma 		0.010 Biomarker disease BEFREE Here, an <i>in situ</i> forming depot-injectable polymeric system was used to deliver BiJ591, a bispecific T-cell engager (BiTE) targeting both prostate-specific membrane antigen (PSMA) and the CD3 T-cell receptor in prostate cancer. 29891487 2018
CUI: C0026764
Disease: Multiple Myeloma
Multiple Myeloma 		0.010 Biomarker disease BEFREE We developed a bispecific T-cell engager (BiTE) targeting BCMA and CD3ɛ (BI 836909) and studied its therapeutic impacts on MM. 28025583 2017